SavedAdd your journal

Journals / Akademik Gastroenteroloji Dergisi / 2022 / Cilt: 21 - Sayı: 3

The changing non-invasive fibrosis index value in patients with hepatitis C treated with direct-acting antiviral agents

Direkt etkili antiviral ajanlarla tedavi olan hepatit C hastalarında non-invaziv fibrozis indeks değerlerinin değişimi

Derya ARI
Dilara TURAN GÖKÇE
Hale GÖKCAN
Ömer ÖZTÜRK
Ferhat BACAKSIZ
Sabite KACAR
Meral AKDOĞAN KAYHAN
Pages
109–114
Publication Date
2022-12-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was a statistically significant drop in mean FIB-4 and APRI scores from baseline to post sustained virologic response (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Aims: About 400 000 patients with hepatitis C virus die from cirrhosis-related complications and hepatocellular carcinoma every year.
📊
Key Findings & Data:Direct-acting antivirals provide a sustained virologic response in more than 90% of patients with hepatitis C virus infection.
💡
Conclusion & Impact:There was a statistically significant drop in mean FIB-4 and APRI scores from baseline to post sustained virologic response (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Direkt etkili anti-viral ajanlar · hepatit C virüsü · non-invasiv fibrozis skorları

Abstract

Background and Aims: About 400 000 patients with hepatitis C virus die from cirrhosis-related complications and hepatocellular carcinoma every year. Direct-acting antivirals provide a sustained virologic response in more than 90% of patients with hepatitis C virus infection. We aimed to evaluate the alteration of the non-invasive fibrosis index in patients with hepatitis C virus who were treated with direct-acting antivirals. Materials and Method: Patients with hepatitis C virus who received a complete course of direct-acting antivirals were analyzed. FIB-4 and APRI were calculated for each patient. Results: Of the 88 patients, 46 (52%) were males, and 21 (23.8%) were cirrhotics. The mean age was 58 years. The significant decrease was showed in the non-invasive scores compared from the baseline to the end of treatment. There was a statistically significant drop in mean FIB-4 and APRI scores from baseline to post sustained virologic response (p

Özet

Giriş ve Amaç: Her yıl yaklaşık 400 000 hepatit C virüs hastası siroza bağlı komplikasyonlardan ve hepatosellüler karsinomadan ölmektedir. Doğrudan etkili antiviraller, hepatit C virüs enfeksiyonu olan hastaların %90’ından fazlasında sürekli bir virolojik yanıt sağlar. Bu çalışmada doğrudan etkili antivirallerle tedavi edilen hepatit C virüslü hastalarda non-invaziv fibrozis indeksindeki değişikliği değerlendirmeyi amaçladık. Gereç ve Yöntem: Doğrudan etkili antiviral teadavisi alan hepatit C virüslü hastalar analiz edildi. Her hasta için FIB-4 ve APRI hesaplandı. Bulgular: Toplam 88 hastanın 46'sı (%52) erkek, 21'i (%23.8) sirotikti. Ortalama yaş 58 yıl idi. Başlangıçtan tedavi bitimine kadar non-invaziv skorlarda anlamlı düşüş gösterildi (p

🔖

Cite This Article

ARI, D., GÖKÇE, D. T., GÖKCAN, H., ÖZTÜRK, Ö., BACAKSIZ, F., KACAR, S., KAYHAN, M. A. (2022). The changing non-invasive fibrosis index value in patients with hepatitis C treated with direct-acting antiviral agents. Akademik Gastroenteroloji Dergisi, Cilt: 21 - Sayı: 3, 109–114. https://ajindex.com/articles/865806

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. World Health Organization. "Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021: actions for impact: web annex 2: data methods." (2021)
  2. Garg G, Dixit VK, Shukla SK, et al. Impact of direct acting antiviral drugs in treatment naïve HCV cirrhosis on fibrosis and severity of liver disease: A real life experience from a tertiary care center of North India. J Clin Exp Hepatol 2018;8:241-9
  3. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study). J Hepatol 2010;53:1013-21
  4. Catanzaro R, Aleo A, Sciuto M, et al. FIB-4 and APRI scores for predicting severe liver fibrosis in chronic hepatitis HCV patients: A monocentric retrospective study. Clin Exp Hepatol 2021;7:111-6
  5. Verlinden W, Bourgeois S, De Maeyer M, et al. Validation of APRI and FIB-4 score in an Antwerp cohort of chronic hepatitis C patients. Acta Gastroenterol Belg 2015;78:373-80
  6. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review. Ann Intern Med 2018;166:637-48
  7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89
  8. Sterling RK, Lissen E, Clumeck N, et al; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-25
  9. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26
  10. Bachofner JA, Valli PV, Kröger A, et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis‐4 score and aspartate aminotransferase‐platelet ratio index. Liver Int 2017;37:369-76
  11. Leuştean A, Popescu C, Nichita L, Tilişcan C, Aramă V. Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy. Exp Ther Med 2021;21:99
  12. Bakır A, Güney M, Erdal H, et al. Assessment of the performances of hepatitis C virus viral markers, age-platelet index and aspartate aminotransferase to alanine aminotr